Protocol to study the antitumor and metabolic effects of intermittent fasting plus cisplatin and metformin in ovarian cancer PDX models.

Authors

Ludovica Perotti, Elena Capellini, Federica Guffanti, Anna Maria Ronchi, Daniela Corna, Domenico Cerullo, Cristina Matteo, Laura Sala, Eugenio Scanziani, Federica Maggi, Melissa Tiddia, Flavia Funari, Giovanna Damia, Laura Brunelli, Francesca Ricci

Published in

STAR protocols. Volume 7. Issue 3. Pages 104736. Jul 27, 2026. Epub Jul 27, 2026.

Abstract

Different dietary regimens are being explored as safe, low-cost approaches to enhance cancer therapy. This protocol describes the evaluation of antitumor and metabolic effects of intermittent fasting (IF) combined with cisplatin and metformin in an ovarian cancer patient-derived xenograft (PDX) model. Procedures include IF cycles, drug administration, antitumor activity assessment, drug quantification in plasma and tumors, toxicity evaluation, and immunohistochemical analyses. For complete information on the generation and use of this protocol, please refer to Capellini et al.¹.

PMID:
42507549
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.